# Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

> **NCT00251303** · PHASE2 · COMPLETED · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 78 (actual)

## Conditions studied

- Obsessive-Compulsive Disorder
- Autism Spectrum Disorder
- Autism
- Asperger Disorder
- Developmental Disorder

## Interventions

- **DRUG:** Riluzole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00251303
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251303, "Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00251303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*